Exelixis (EXEL) Competitors

Exelixis logo
$64.63 -1.20 (-1.82%)
Closing price 11/20/2026 04:00 PM Eastern
Extended Trading
$63.16 -1.47 (-2.27%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

EXEL vs. ARGX, NTRA, BIIB, RVMD, and GMAB

Should you buy Exelixis stock or one of its competitors? Exelixis's main competitors and comparable companies include argenex (ARGX), Natera (NTRA), Biogen (BIIB), Revolution Medicines (RVMD), and Genmab A/S (GMAB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Exelixis compare to argenex?

Exelixis (NASDAQ:EXEL) and argenex (NASDAQ:ARGX) are both large-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, media sentiment, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Exelixis has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, argenex has a beta of 0.48, indicating that its stock price is 52% less volatile than the broader market.

In the previous week, Exelixis had 6 more articles in the media than argenex. MarketBeat recorded 10 mentions for Exelixis and 4 mentions for argenex. Exelixis' average media sentiment score of 0.35 beat argenex's score of 0.03 indicating that Exelixis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exelixis
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
argenex
0 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Exelixis currently has a consensus price target of $58.62, suggesting a potential downside of 9.31%. argenex has a consensus price target of $1,163.18, suggesting a potential upside of 25.70%. Given argenex's stronger consensus rating and higher possible upside, analysts plainly believe argenex is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exelixis
1 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.41
argenex
0 Sell rating(s)
6 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.82

argenex has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than argenex, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exelixis$2.32B6.80$782.57M$3.3419.35
argenex$4.25B13.70$1.29B$28.6632.29

85.3% of Exelixis shares are held by institutional investors. Comparatively, 60.3% of argenex shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 2.4% of argenex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Exelixis has a net margin of 35.45% compared to argenex's net margin of 31.66%. argenex's return on equity of 47.70% beat Exelixis' return on equity.

Company Net Margins Return on Equity Return on Assets
Exelixis35.45% 45.54% 33.90%
argenex 31.66%47.70%40.12%

Summary

argenex beats Exelixis on 11 of the 16 factors compared between the two stocks.

How does Exelixis compare to Natera?

Exelixis (NASDAQ:EXEL) and Natera (NASDAQ:NTRA) are both large-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, valuation, risk, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

85.3% of Exelixis shares are held by institutional investors. Comparatively, 99.9% of Natera shares are held by institutional investors. 2.6% of Exelixis shares are held by insiders. Comparatively, 5.1% of Natera shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Exelixis had 4 more articles in the media than Natera. MarketBeat recorded 10 mentions for Exelixis and 6 mentions for Natera. Exelixis' average media sentiment score of 0.35 beat Natera's score of 0.25 indicating that Exelixis is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exelixis
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Natera
2 Very Positive mention(s)
1 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Exelixis has a beta of 0.45, indicating that its stock price is 55% less volatile than the broader market. Comparatively, Natera has a beta of 1.55, indicating that its stock price is 55% more volatile than the broader market.

Exelixis presently has a consensus target price of $58.62, suggesting a potential downside of 9.31%. Natera has a consensus target price of $396.93, suggesting a potential upside of 45.35%. Given Natera's stronger consensus rating and higher possible upside, analysts clearly believe Natera is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exelixis
1 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.41
Natera
2 Sell rating(s)
2 Hold rating(s)
17 Buy rating(s)
2 Strong Buy rating(s)
2.83

Exelixis has a net margin of 35.45% compared to Natera's net margin of -5.66%. Exelixis' return on equity of 45.54% beat Natera's return on equity.

Company Net Margins Return on Equity Return on Assets
Exelixis35.45% 45.54% 33.90%
Natera -5.66%-8.61%-5.93%

Exelixis has higher revenue and earnings than Natera. Natera is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exelixis$2.32B6.80$782.57M$3.3419.35
Natera$2.31B17.17-$208.16M-$1.14N/A

Summary

Exelixis beats Natera on 9 of the 17 factors compared between the two stocks.

How does Exelixis compare to Biogen?

Biogen (NASDAQ:BIIB) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, institutional ownership, risk, media sentiment, valuation, dividends and profitability.

In the previous week, Biogen had 37 more articles in the media than Exelixis. MarketBeat recorded 47 mentions for Biogen and 10 mentions for Exelixis. Biogen's average media sentiment score of 0.79 beat Exelixis' score of 0.35 indicating that Biogen is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
22 Very Positive mention(s)
5 Positive mention(s)
15 Neutral mention(s)
3 Negative mention(s)
1 Very Negative mention(s)
Positive
Exelixis
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

Biogen currently has a consensus price target of $255.45, suggesting a potential upside of 2.35%. Exelixis has a consensus price target of $58.62, suggesting a potential downside of 9.31%. Given Biogen's stronger consensus rating and higher probable upside, equities analysts clearly believe Biogen is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
1 Sell rating(s)
10 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.67
Exelixis
1 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.41

87.9% of Biogen shares are held by institutional investors. Comparatively, 85.3% of Exelixis shares are held by institutional investors. 0.3% of Biogen shares are held by company insiders. Comparatively, 2.6% of Exelixis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Biogen has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$9.89B3.73$1.29B$2.34106.66
Exelixis$2.32B6.80$782.57M$3.3419.35

Biogen has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.45, suggesting that its stock price is 55% less volatile than the broader market.

Exelixis has a net margin of 35.45% compared to Biogen's net margin of 3.37%. Exelixis' return on equity of 45.54% beat Biogen's return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen3.37% 9.38% 5.69%
Exelixis 35.45%45.54%33.90%

Summary

Biogen beats Exelixis on 9 of the 16 factors compared between the two stocks.

How does Exelixis compare to Revolution Medicines?

Exelixis (NASDAQ:EXEL) and Revolution Medicines (NASDAQ:RVMD) are both large-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, profitability, analyst recommendations, valuation, dividends and media sentiment.

In the previous week, Revolution Medicines had 16 more articles in the media than Exelixis. MarketBeat recorded 26 mentions for Revolution Medicines and 10 mentions for Exelixis. Revolution Medicines' average media sentiment score of 0.44 beat Exelixis' score of 0.35 indicating that Revolution Medicines is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exelixis
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral
Revolution Medicines
8 Very Positive mention(s)
4 Positive mention(s)
12 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Exelixis has higher revenue and earnings than Revolution Medicines. Revolution Medicines is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exelixis$2.32B6.80$782.57M$3.3419.35
Revolution Medicines$11.58M3,000.27-$1.13B-$9.11N/A

Exelixis has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market. Comparatively, Revolution Medicines has a beta of 1.44, indicating that its share price is 44% more volatile than the broader market.

Exelixis currently has a consensus target price of $58.62, indicating a potential downside of 9.31%. Revolution Medicines has a consensus target price of $262.75, indicating a potential upside of 63.57%. Given Revolution Medicines' stronger consensus rating and higher possible upside, analysts clearly believe Revolution Medicines is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exelixis
1 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.41
Revolution Medicines
1 Sell rating(s)
1 Hold rating(s)
21 Buy rating(s)
1 Strong Buy rating(s)
2.92

Exelixis has a net margin of 35.45% compared to Revolution Medicines' net margin of 0.00%. Exelixis' return on equity of 45.54% beat Revolution Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Exelixis35.45% 45.54% 33.90%
Revolution Medicines N/A -84.51%-51.97%

85.3% of Exelixis shares are owned by institutional investors. Comparatively, 94.3% of Revolution Medicines shares are owned by institutional investors. 2.6% of Exelixis shares are owned by company insiders. Comparatively, 7.6% of Revolution Medicines shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Revolution Medicines beats Exelixis on 9 of the 16 factors compared between the two stocks.

How does Exelixis compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and Exelixis (NASDAQ:EXEL) are both large-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, analyst recommendations, institutional ownership and media sentiment.

Genmab A/S currently has a consensus price target of $53.50, indicating a potential upside of 5.90%. Exelixis has a consensus price target of $58.62, indicating a potential downside of 9.31%. Given Genmab A/S's stronger consensus rating and higher probable upside, equities research analysts clearly believe Genmab A/S is more favorable than Exelixis.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Genmab A/S
0 Sell rating(s)
1 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
3.00
Exelixis
1 Sell rating(s)
9 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.41

Genmab A/S has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market. Comparatively, Exelixis has a beta of 0.45, meaning that its stock price is 55% less volatile than the broader market.

In the previous week, Exelixis had 4 more articles in the media than Genmab A/S. MarketBeat recorded 10 mentions for Exelixis and 6 mentions for Genmab A/S. Genmab A/S's average media sentiment score of 0.40 beat Exelixis' score of 0.35 indicating that Genmab A/S is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Genmab A/S
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Exelixis
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
1 Very Negative mention(s)
Neutral

7.1% of Genmab A/S shares are owned by institutional investors. Comparatively, 85.3% of Exelixis shares are owned by institutional investors. 1.5% of Genmab A/S shares are owned by company insiders. Comparatively, 2.6% of Exelixis shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Exelixis has a net margin of 35.45% compared to Genmab A/S's net margin of 16.97%. Exelixis' return on equity of 45.54% beat Genmab A/S's return on equity.

Company Net Margins Return on Equity Return on Assets
Genmab A/S16.97% 13.67% 6.42%
Exelixis 35.45%45.54%33.90%

Genmab A/S has higher revenue and earnings than Exelixis. Exelixis is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Genmab A/S$3.72B8.48$963M$1.1743.18
Exelixis$2.32B6.80$782.57M$3.3419.35

Summary

Genmab A/S beats Exelixis on 9 of the 16 factors compared between the two stocks.

Get Exelixis News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXEL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EXEL vs. The Competition

MetricExelixisBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$16.37B$4.08B$7.80B$11.72B
Dividend YieldN/A3.63%2.47%4.72%
P/E Ratio19.3523.4832.6028.82
Price / Sales6.8015.278.125.42
Price / Cash22.1722.9521.0521.90
Price / Book8.594.004.263.50
Net Income$782.57M-$24.08M$3.51B$394.12M
1 Month Performance0.08%-13.57%-10.57%-12.04%
1 Year Performance52.03%-7.97%-4.78%-11.42%

Exelixis Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EXEL
Exelixis
2.1905 of 5 stars
$64.63
-1.8%
$58.62
-9.3%
+54.7%$16.37B$2.32B19.351,077
ARGX
argenex
4.533 of 5 stars
$947.52
-0.4%
$1,163.18
+22.8%
+0.7%$59.59B$5.82B33.061,863
NTRA
Natera
2.8762 of 5 stars
$287.47
-0.4%
$394.31
+37.2%
+21.1%$41.69B$2.31BN/A6,140
BIIB
Biogen
2.9206 of 5 stars
$250.79
-0.3%
$254.41
+1.4%
+48.4%$37.07B$9.89B107.187,500
RVMD
Revolution Medicines
3.0428 of 5 stars
$162.69
-2.5%
$262.75
+61.5%
+129.9%$35.19B$11.58MN/A883

Related Companies and Tools


This page (NASDAQ:EXEL) was last updated on 11/21/2026 by MarketBeat.com Staff.
From Our Partners